Loading
A phase 2 trial of Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Lantern Pharma Inc., now recruiting.
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma is a phase 2 interventional study registered as NCT05456256 by Lantern Pharma Inc., with 90 participants planned, started 2023-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: LP-300, Pemetrexed and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, Carboplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/